India's Diabetes Epidemic Meets GLP-1 Drugs: A Case for Controlled Access

The Lift Line

A drug this good should not be rationed by price alone, and it should not be handed out by price alone either.

Why This Editorial Matters for Your Exam

Health policy answers on India’s disease burden often stop at citing prevalence numbers. This editorial supplies the harder governance question that follows a genuinely effective new therapy: when a drug has dual approved uses, one clinical and one aesthetic-adjacent, who gets first access, and what mechanism decides that, rather than leaving it to who can pay.

GS Paper 2: Issues relating to development and management of Social Sector/Services relating to Health; government policies and interventions for development in the health sector.

GS Paper 3: Science and technology developments and their applications; issues relating to intellectual property rights in the pharmaceutical sector.

Background and Context

India’s diabetes burden is large and well documented. The ICMR-INDIAB study, the country’s most comprehensive national survey on the subject, estimates 101 million adults living with diabetes and a further 136 million in the prediabetic stage, drawing on data collected across all states and union territories. This is the reference figure Indian health policy now works from.

GLP-1 receptor agonist drugs, a class that includes semaglutide, entered clinical use as a treatment for type 2 diabetes and have since accumulated strong trial evidence for cardiovascular and mortality benefit in appropriately selected patients, benefits that go beyond blood sugar control alone. The same appetite-suppressing mechanism that helps regulate blood sugar has also made these drugs effective, and commercially prominent, for weight loss, creating a second, much larger potential market beyond the diabetic population.

Indu Bhushan, the author, is the founding CEO of the National Health Authority (2018 to 2021), the body that designed and implemented Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY), India’s flagship public health insurance scheme. That background is directly relevant to why his proposal favours a controlled, phased introduction over an open market rollout.

The Analysis

1. The scale of the underlying disease burden is not in dispute. At 101 million diabetic and 136 million prediabetic Indians, this is one of the largest single disease burdens the health system manages, and the clinical case for a genuinely effective new therapy is strong on its own terms.

2. The dual approval is the actual policy problem. A drug approved for both diabetes management and weight loss does not automatically serve the diabetic population first when access is left to the market; ability to pay, not clinical need, tends to determine who obtains the drug first in an unrestricted rollout.

3. Affordability is a real constraint, not a marginal one. Even the lower end of the current Indian pricing range for these drugs represents a significant recurring cost for most households, meaning that without a designed access mechanism, benefit is likely to concentrate among patients who could afford care regardless.

4. A phased pilot is a governance instrument India already uses. Testing an intervention in a defined number of states before national scale-up, with eligibility criteria and monitoring, is a standard tool for sequencing high-cost health interventions, distinct from either an unrestricted commercial launch or an indefinite delay.

5. The author’s institutional background gives the proposal specific credibility. Having built Ayushman Bharat PM-JAY, Bhushan has direct experience of what happens when a large health intervention scales nationally without adequate cost and equity safeguards built in from the start.

6. The counter-argument about pace deserves serious weight. A pilot confined to four or five states, without a fixed timeline for evaluation and expansion, risks becoming a permanent gatekeeping mechanism rather than a stepping stone, leaving most of a 100-million-plus patient population without access to a proven therapy for years.

Data and Institutions Vault

Prelims-grade facts:

• ICMR-INDIAB study: 101 million Indians living with diabetes, 136 million prediabetic, India’s standard national reference figure
• GLP-1 (glucagon-like peptide-1): a naturally occurring gut incretin hormone; GLP-1 receptor agonist drugs (including semaglutide) mimic it
• Mechanism: stimulates insulin secretion, slows gastric emptying, increases satiety
• Dual approved use: type 2 diabetes management AND weight loss/obesity management
• Indu Bhushan: founding CEO, National Health Authority (2018 to 2021); architect of Ayushman Bharat PM-JAY
• Proposed access model: phased pilot in four or five states, with strict eligibility criteria and monitoring before wider rollout

Watch the trap: do not write that GLP-1 drugs are approved in India only for weight loss; the diabetes indication came first and remains the primary clinical justification for subsidised or insurance-linked access.

The Debate

Argument FOR a controlled, phased rollout. A dual-use drug with strong commercial demand for its weight-loss indication will, left to the market, direct scarce affordable access toward patients who can already pay rather than toward the diabetic population with the strongest clinical case. Eligibility criteria and a phased pilot are the tools that correct for this, and testing the model in four or five states before national scale-up limits the fiscal and administrative risk of getting the design wrong at full scale.

Argument AGAINST prioritising caution over pace. A disease burden of over 100 million people is not well served by a pilot confined to a handful of states with no stated timeline for expansion; the language of resisting “commercial interests” can just as easily become a justification for indefinite delay, denying a proven, evidence-backed therapy to patients who need it now, particularly those with diabetes and documented cardiovascular risk.

Balanced verdict. The two positions are reconcilable if the pilot is designed with a fixed evaluation window and published outcome data rather than left open-ended: strict eligibility criteria protect equity of access, while a defined timeline for expansion protects against caution becoming permanent gatekeeping. The design choice that matters most is not whether to phase the rollout, but whether the phase has a deadline.

How to Think About This

The transferable pattern: when a new health technology has more than one approved use, and the uses differ sharply in who can afford them, ask who captures access first under an unrestricted rollout, and build the eligibility rule around correcting that, not around slowing adoption for its own sake.

Any dual-use or multi-indication technology, a drug, a diagnostic tool, a therapy with both a high-need and a high-willingness-to-pay application, creates the same distributional risk: the higher-willingness-to-pay use tends to crowd out the higher-need use unless a deliberate access rule intervenes. The correct response is not to resist adoption but to design the eligibility criterion around the gap between need and ability to pay.

This same structure recurs in genomic testing, where diagnostic uses compete with elective or lifestyle applications for laboratory capacity; in advanced diagnostic imaging, where screening for high-risk patients competes with elective use; and in newer biologic therapies more broadly, where a single molecule’s multiple approved indications create exactly this kind of access-prioritisation problem.

Diagram-in-Words

THE GLP-1 ACCESS PROBLEM

DIABETES BURDEN (India)
101 million diabetic + 136 million prediabetic
        |
        v
GLP-1 DRUG (dual approved use)
        |
   ______|______
   |           |
DIABETES    WEIGHT LOSS
MANAGEMENT  (aesthetic-adjacent demand)
   |           |
strongest    higher willingness
clinical     to pay, often
need, often  wealthier patients
lower
ability
to pay
   |           |
   v           v
UNRESTRICTED MARKET ROLLOUT
   =
benefit concentrates in weight-loss use,
diabetic population underserved

VS.

PHASED PILOT (4-5 states) + ELIGIBILITY CRITERIA
   =
access directed to diabetic/cardiovascular-risk
patients first, evaluated, then expanded

RISK IF NO TIMELINE SET: pilot becomes permanent gatekeeping

Takeaway Box

Lift line for an answer:

An unrestricted rollout lets the market decide who gets the drug. A phased, criteria-based rollout lets the disease burden decide instead.

Prelims hooks: ICMR-INDIAB: 101 million diabetic, 136 million prediabetic; GLP-1 mechanism (insulin secretion, gastric emptying, satiety); dual approved use (diabetes AND weight loss); Indu Bhushan, founding CEO National Health Authority (2018 to 2021), architect of Ayushman Bharat PM-JAY; proposed pilot in four or five states.

Ethics and interview angle: when a limited-access health intervention has both a high-need, low-ability-to-pay population and a high-demand, high-ability-to-pay population, does the state have an obligation to actively restrict the second group’s access in order to protect the first, or does that cross into paternalism?

PYQ linkage: UPSC has repeatedly examined universal health coverage, NCD (non-communicable disease) burden and equitable access to health technology; this editorial supplies a live, named case, a specific dual-use drug class, to argue that access design, not just availability, determines equity outcomes.

Probable question: “A health technology with dual approved uses, one addressing a large disease burden and one addressing a smaller but higher-paying demand, cannot be left to an unrestricted market rollout without producing an inequitable outcome.” Discuss with reference to GLP-1 drug access in India.

Sources: Hindustan Times, ICMR, PIB

Source: India's Diabetes Epidemic Meets GLP-1 Drugs: A Case for Controlled Access — Ujiyari.com | Free UPSC & State PCS Editorial Analysis